Cohen & Steers (CNS) Stock

NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Cohen & Steers Income Opportunities REIT, Inc. ("CNSREIT") announced today its acquisition of Bridgepointe Shopping Center, an open-air community shopping center in San Mateo, California. The acquisition was made through a programmatic joint venture with Sterling Organization ("Sterling"), a real estate investment firm with extensive expertise in shopping centers in the U.S. This is CNSREIT's third acquisition with Sterling Organization and fourth open-air shopping center acquisition in the portfolio.

NEW YORK , Dec. 18, 2024 /PRNewswire/ -- The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for January, February, and March 2025, as summarized in the charts below: Ticker Fund Name Monthly Dividend FOF Cohen & Steers Closed-End Opportunity Fund, Inc. $0.087 LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc. $0.131 PSF Cohen & Steers Select Preferred and Income Fund, Inc. $0.126 PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund $0.134 RFI Cohen & Steers Total Return Realty Fund, Inc. $0.080 RLTY Cohen & Steers Real Estate Opportunities and Income Fund $0.110 RNP Cohen & Steers REIT and Preferred and Income Fund, Inc. $0.136 RQI Cohen & Steers Quality Income Realty Fund, Inc. $0.080 UTF Cohen & Steers Infrastructure Fund, Inc. $0.155   Distributions will be made on the following schedule: Month Ex-Dividend/ Record Date Payable Date January Jan. 14, 2025 Jan. 31, 2025 February Feb. 11, 2025 Feb. 28, 2025 March Mar. 11, 2025 Mar. 31, 2025   Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund, Cohen & Steers Real Estate Opportunities and Income Fund, Cohen & Steers Limited Duration Preferred and Income Fund, Inc., and Cohen & Steers Select Preferred and Income Fund, Inc. pay regular monthly cash distributions to common shareholders at a level rate that may be adjusted from time to time. Each of these fund's distributions reflect net investment income and may also include net realized capital gains and/or return of capital.

Corero Network Security, known for its expertise in protecting against distributed denial of service (DDOS) attacks, is excited to announce that it will take part in The Microcap Conference 2025. This important event for companies and investors looking for growth will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.

CNS Pharmaceuticals, Inc. is hosting a live webcast discussion with leading experts on Glioblastoma Multiforme (GBM), a severe type of brain cancer that typically has a survival rate of only 14 to 16 months after diagnosis. The Virtual Analyst & Investor Day will take place on December 11th from 11:30 AM to 1:00 PM ET, featuring key speakers from the company and prominent opinion leaders in the field. You can register for the event here.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) is a biopharmaceutical company focused on creating new treatments for brain and central nervous system cancers. They have announced that their abstract will be presented as a poster at the 29th Annual Meeting of the Society for Neuro-Oncology, taking place from November 21-24, 2024, in Houston, TX. The presentation will cover an update on a significant trial, CNS-201, which compares Berubicin to other treatments.

CNS Pharmaceuticals, Inc. has reported its financial results for the third quarter of 2024, highlighting progress in their key GBM study with Berubicin, which is expected to yield primary analysis data in early 2025. The company has also improved its financial position to support operations beyond the data release and expanded its pipeline by acquiring TPI 287, a promising treatment for brain cancers. Overall, the team has achieved significant advancements throughout 2024.

NEW YORK, Nov. 11, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that their preliminary assets under management were $89.7 billion as of October 31, 2024, which is a drop of $2.0 billion from $91.8 billion on September 30, 2024. This decline was mainly caused by a market loss of $2.3 billion and $150 million in distributions, although they did see a net inflow of $454 million.

On November 8, 2024, Cohen & Steers, Inc. (NYSE: CNS) announced that its Board of Directors has named Karen Wilson Thissen as a new director. In addition, she will serve on the Board's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage pharmaceutical company focused on creating treatments for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases. The company has announced that it will present positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial at the CNS Summit 2024, which will be held from November 10-13 in Boston, Massachusetts.